The independent source for health policy research, polling, and news.
Medical Debt: The Canary in the Coal Mine for Health Care Affordability
With Vice President Harris promising to address medical debt as part of her economic plan, KFF Executive Vice President for Health Policy Larry Levitt explores why it is a symptom of the broader problem of affordable health care and reviews recent efforts to address it in this JAMA Health Forum post.
Column Read PostThe First-Ever Government Negotiation Process for Drugs Has Finished, But the Politics Are Ongoing
This post for Health Affairs Forefront examines how the results of the first-ever Medicare drug price negotiations will generate savings for the government and for Medicare beneficiaries, and how candidates’ views on the issue could play a role in the upcoming elections and in the future of government negotiation.
Read PostThe Implications of the Public’s Pre-existing Condition Amnesia
KFF’s Larry Levitt discusses waning awareness of the Affordable Care Act’s provisions protecting people with pre-existing conditions and examines the Republican Study Committee’s budget proposal, which proposes to repeal the provisions.
Read PostWhat Would Another Trump Presidency Mean for Health Care?
In a new column in JAMA Health Forum, Larry Levitt, KFF’s executive vice president for health policy, explores what a second Trump presidency might mean for health policy based on his record and remarks, including potentially weakening the Affordable Care Act, reducing federal Medicaid costs, and restricting access to abortion.
Column Read PostComplexity in Our Health Care System is the Enemy of Access and Affordability
In this JAMA Health Forum column, KFF’s Drew Altman and Larry Levitt examine how the complexity of the health care system – with all of its red tape – can be as big a problem for patients as the traditional big three problems of costs, quality and access.
Column Read PostThe 4 Arguments You Will Hear Against Drug Price Negotiation
As the Biden administration begins the process of negotiation drug prices for Medicare as authorized in the Inflation Reduction Act, KFF’s Larry Levitt probes some of the arguments against it and the policy and political implications of the debate in this New York Times op-ed column.
Op-Ed Read Post